Leqvio Cognitive Function Impact: What the Evidence Actually Shows

Does Inclisiran Affect Cognitive Function?

Based on available phase 3 data, inclisiran does not impair cognitive function. The ORION-10 (N=1,561) and ORION-11 (N=1,617) trials, reported together in the New England Journal of Medicine, found no statistically significant excess of neurocognitive adverse events in the inclisiran arms compared with placebo over 18 months of follow-up [1]. Rates of reported memory disturbance, confusion, and related terms were low and balanced between groups.

This finding matters because patients asking about "Leqvio cognitive function impact" are often recalling older, largely debunked concerns that surfaced during early statin research. Inclisiran is not a statin. It is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA in the liver, and its pharmacology raises different questions about brain biology than lipophilic statins do.

Why the Concern Arose in the First Place

The cognitive safety question for any lipid-lowering agent traces partly to two sources. First, a 2012 FDA safety communication noted case reports of memory impairment with statins, leading to label updates [2]. Second, early mechanistic concern held that very low LDL-C might deprive neurons of needed cholesterol. Neither concern has translated into measurable harm in large randomized trials for inclisiran or its PCSK9 inhibitor predecessors.

What the ORION Data Actually Measured

ORION-10 and ORION-11 collected adverse events through systematic patient reporting at each visit. Neurological and psychiatric events were coded using MedDRA preferred terms. Neither trial was powered specifically for neurocognitive outcomes, which is a limitation worth acknowledging. Dedicated cognitive testing, such as the telephone-based cognitive assessment used in EBBINGHAUS, was not embedded in the ORION protocols.

The absence of a formal neurocognitive battery in ORION-10 and ORION-11 means clinicians cannot draw definitive conclusions in either direction from those data alone. What can be said is that spontaneous adverse event reporting through 18 months showed no signal.

The PCSK9 Inhibitor Cognitive Evidence Base

Inclisiran shares its pharmacological target, PCSK9, with the monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent). The cognitive safety evidence from those agents is substantially deeper and directly informs expectations for inclisiran.

EBBINGHAUS: The Landmark Cognitive Sub-Study

The EBBINGHAUS trial enrolled 1,974 participants from the FOURIER cardiovascular outcomes trial and administered formal cognitive testing at multiple time points over a median of 19 months [3]. The primary endpoint was the Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory strategy score. Evolocumab produced no significant difference versus placebo on this primary endpoint (P<0.001 non-inferiority margin met). Secondary domains, including executive function, attention, and memory, were similarly unaffected.

The EBBINGHAUS investigators, writing in the New England Journal of Medicine, stated: "There was no significant between-group difference in any cognitive domain, including in participants who had achieved LDL cholesterol levels of less than 25 mg/dL" [3]. That sub-25 mg/dL finding is particularly relevant for inclisiran because some patients on the drug reach comparable depths.

FOURIER Open-Label Extension

The FOURIER open-label extension (FOURIER-OLE) followed patients for up to 8.4 years of evolocumab exposure [4]. Published in Circulation in 2023, it found no increase in neurocognitive adverse events with sustained, very deep LDL-C lowering. Median achieved LDL-C in the long-term evolocumab group was 30 mg/dL. At that level, across more than 8 years, no cognitive harm signal emerged.

ODYSSEY OUTCOMES and Alirocumab

The ODYSSEY OUTCOMES trial (N=18,924) studied alirocumab after acute coronary syndrome. A pre-specified neurocognitive safety analysis found neurocognitive events in 1.2% of the alirocumab group versus 1.3% with placebo, a non-significant difference [5]. The American College of Cardiology and American Heart Association 2018 cholesterol guideline explicitly noted the available evidence did not support a causal link between PCSK9 inhibition and cognitive impairment [6].

Mechanism: Could Deep LDL-C Lowering Theoretically Harm the Brain?

This is a reasonable mechanistic question. The brain synthesizes its own cholesterol; it does not rely on circulating LDL-C because LDL particles cannot cross the intact blood-brain barrier (BBB) [7]. Brain cholesterol homeostasis is governed largely by local astrocyte synthesis via HMGCR and ABCA1-mediated transport, not by plasma LDL levels.

Inclisiran's Site of Action

Inclisiran is taken up almost exclusively by hepatocytes through the asialoglycoprotein receptor (ASGPR). The drug is not detected at meaningful concentrations in cerebrospinal fluid in preclinical studies submitted to the FDA [8]. Because inclisiran acts only in the liver, and because the BBB restricts LDL-particle entry into the CNS regardless, two separate barriers exist between inclisiran's mechanism and neuronal cholesterol pools.

PCSK9 in the Brain

PCSK9 is expressed in neurons, where it modulates synaptic plasticity through effects on NMDA and APOE receptors [9]. Loss-of-function PCSK9 variants in humans, the genetic models most analogous to PCSK9 inhibition, have not been associated with cognitive decline in population genetics studies. The UK Biobank analysis of over 300,000 participants found no association between PCSK9 loss-of-function alleles and dementia risk [10].

What the Current Inclisiran Label Says About Cognition

The FDA-approved prescribing information for inclisiran, last updated following the December 2021 approval, contains no boxed warning, no warning, and no precaution related to cognitive function [8]. The adverse reactions table from the pooled ORION-10 and ORION-11 data lists injection-site reactions as the most common treatment-emergent adverse event (8.2% inclisiran vs. 1.8% placebo). Nervous system disorders were reported in 7.4% of inclisiran patients and 7.1% of placebo patients, a difference that was not statistically significant.

Clinicians counseling patients should be able to say with confidence that the FDA labeling carries no cognitive caution, while also noting that 18-month phase 3 trials cannot rule out effects that might only appear over decades.

Long-Term Outlook: What We Still Do Not Know

Eighteen months of follow-up in ORION-10 and ORION-11 does not address the question of cognitive effects over 10 or 20 years of twice-yearly inclisiran dosing. That gap in the literature is real.

Ongoing and Planned Studies

The ORION-4 cardiovascular outcomes trial (N=15,000, 5-year follow-up) is the largest inclisiran study underway and will generate a substantially longer safety dataset [11]. Cognitive events are collected as adverse events in that trial, though dedicated neuropsychological testing has not been confirmed as a co-primary or secondary endpoint in public registrations. Results are expected around 2026 to 2027.

A separate line of evidence may come from Mendelian randomization studies. These use naturally occurring genetic variants as proxies for long-term PCSK9 suppression and can model decades of exposure in population cohorts. Published Mendelian randomization analyses have consistently shown either neutral or directionally favorable associations between reduced PCSK9 activity and cognitive outcomes [10].

The Cardiovascular-Cognition Link

One underappreciated angle: cardiovascular disease and its risk factors independently damage cognition. Atherosclerosis reduces cerebral perfusion, and recurrent small-vessel strokes contribute to vascular dementia [12]. By lowering LDL-C by approximately 50% and reducing cardiovascular events, inclisiran might, through a secondary pathway, protect cognition in high-risk patients. That hypothesis has not been tested in a randomized trial specifically designed around cognitive endpoints, but the mechanistic rationale is grounded in established vascular biology.

Clinical Counsel: How to Talk to Patients About This

Patients with familial hypercholesterolemia (HeFH) or established ASCVD who are considering inclisiran often raise the cognitive question after reading about statins or after a family member reported memory issues on a different cholesterol drug. The conversation has a few concrete steps.

Separate Inclisiran from Statin Cognitive Concerns

Statins are lipophilic small molecules that cross the BBB; some observational data, though not randomized trial data, link high-dose lipophilic statins to subjective memory complaints [2]. Inclisiran does not cross the BBB. The pharmacological comparison is not valid, and patients benefit from having that distinction made clearly.

Acknowledge What Remains Unknown

Honest counseling includes telling patients that inclisiran has 18 months of controlled data and that longer-term cognitive data, comparable to the 8.4-year FOURIER-OLE for evolocumab, do not yet exist for inclisiran specifically. Patients who want the deepest available evidence may reasonably ask about the evolocumab literature as the best available analogy.

Weigh the Cardiovascular Benefit

For a patient with HeFH and LDL-C of 190 mg/dL despite maximally tolerated statin therapy, the cardiovascular benefit of adding inclisiran, a projected 50% further reduction in LDL-C, is substantial. The ACC/AHA guideline notes that for patients with very high cardiovascular risk and LDL-C persistently above 70 mg/dL on maximally tolerated statin therapy, PCSK9 inhibition offers a class I, level A recommendation [6]. That risk-benefit calculation currently tilts strongly toward treatment in eligible patients.

Monitoring in Practice

No specific cognitive monitoring protocol is required by the FDA label for inclisiran. A practical approach used at some lipid specialty centers involves a brief baseline cognitive screen, such as the Montreal Cognitive Assessment (MoCA), in patients older than 70 or those with subjective memory complaints before starting any new lipid-lowering agent. Follow-up scoring at 12 months provides a personal baseline comparison. This is not an FDA requirement and is not standard of care, but it addresses patient anxiety with objective data.

Inclisiran Versus Evolocumab and Alirocumab: Cognitive Safety Comparison

| Agent | Mechanism | Longest Controlled Follow-Up | Dedicated Cognitive Testing | Cognitive AE Signal | |---|---|---|---|---| | Inclisiran (Leqvio) | siRNA / PCSK9 mRNA silencing | 18 months (ORION-10/11) | No (AE reporting only) | None detected | | Evolocumab (Repatha) | Monoclonal antibody / PCSK9 binding | 8.4 years (FOURIER-OLE) | Yes (EBBINGHAUS CANTAB) | None detected | | Alirocumab (Praluent) | Monoclonal antibody / PCSK9 binding | 5 years (ODYSSEY OUTCOMES) | Limited (AE analysis) | None detected |

All three agents target the same pathway. The cognitive safety profile across the class is consistent, and no agent has produced a reproducible cognitive harm signal in a randomized controlled trial.

Key Takeaways for Prescribers

Inclisiran achieves approximately 50% LDL-C reduction with twice-yearly dosing. The ORION-10 (N=1,561) and ORION-11 (N=1,617) trials found no excess of neurocognitive adverse events versus placebo at 18 months [1]. The broader PCSK9 inhibitor class evidence, spanning EBBINGHAUS (N=1,974, 19 months of formal neuropsychological testing) [3] and FOURIER-OLE (up to 8.4 years) [4], shows no cognitive harm with deep, sustained LDL-C lowering. The FDA label contains no cognitive warning. Ongoing long-term data from ORION-4 will add substantially to the evidence base around 2026 to 2027 [11].

For patients eligible for inclisiran under ACC/AHA class I criteria, current evidence does not support withholding treatment due to cognitive concerns. Patients who ask specifically about memory and thinking should receive a direct explanation of the BBB-impermeable pharmacology of inclisiran and a summary of the EBBINGHAUS findings as the most rigorous available cognitive dataset in the PCSK9 class.